IOT Innovotech Inc

Innovotech Inc. (TSX VENTURE:IOT), a pioneer in the field of biofilm product
development, is pleased to announce that its proprietary BEST(TM) (Biofilm
Eradication Surface Test) assay for external efficacy testing was a key element
in the recent FDA 510(k) market clearance of Teleflex Incorporated's
ArrowEVOLUTION(TM), an advanced anti-microbial peripherally-inserted central
catheter. Arrow EVOLUTION with Chlorag+ard(TM) technology provides a unique
option to clinicians in their efforts to protect against central line-associated
bloodstream infections, a major contributor to hospital acquired infections.


"Our recent project with Teleflex is yet another demonstration of Innovotech's
expertise in microbial biofilms and its distinguished track record in meeting
client's needs," said Ken Boutilier, President and CEO of Innovotech Inc.
"Biofilms cause major problems in human health, from hospital-acquired
infections (such as those caused by catheters) to food safety.


"FDA market clearance of the ArrowEVOLUTION(TM) catheter with Chlorag+ard(TM)
technology enhances Teleflex's position as a leading global provider of medical
technology products," said Barry McBride, Teleflex Chief Technology Officer.
"Innovotech's sense of urgency, understanding of the requirements and their
extensive commercial knowledge of biofilm microbiology were significant
contributing factors in the development and execution of external efficacy
testing for submission."


About Innovotech Inc.:

Innovotech Inc. is a pioneer in the field of biofilm product development,
focused on providing innovative and practical solutions to medical, agricultural
and industrial problems caused by microbial biofilms. Biofilms are responsible
for a host of diseases both in human health and agriculture due to their
inherent resistance to existing antibiotics and disinfectants. There are
currently no antibiotics, disinfectants, diagnostics or regulatory standards
designed specifically for biofilm-forming organisms.


Innovotech currently has two products in advanced stages of development: bioFILM
PA(TM), the first diagnostic kit to assist physicians in the selection of the
most effective combination antibiotic treatment of patients with biofilm-based
chronic lung infections and Agress(TM), a unique, environmentally friendly seed
treatment and plant spray designed to protect crops against both bacterial and
fungal infections.


This document may contain forward-looking statements that are predictive in
nature and subject to risks and uncertainties that cannot be predicted or
quantified; consequently, actual results may differ materially from past results
and those expressed or implied by any forward-looking statements. Factors that
could cause or contribute to such risks or uncertainties include, but are not
limited to: the regulatory environment including the difficulty of predicting
regulatory outcomes; changes in the value of the Canadian dollar; the Company's
reliance on a small number of customers including government organizations;
fluctuations in operating results; government policies or actions; progress and
cost of clinical trials; reliance on key strategic relationships; uncertainty
related to intellectual property protection and potential costs associated with
its defense; the Company's exposure to lawsuits and other matters beyond the
control of management. Should known or unknown risks or uncertainties
materialize, or should management's assumptions prove inaccurate, actual results
could vary materially from those anticipated. The Company undertakes no
obligation to publicly make or update any forward-looking statements, except as
required by applicable law.

Innovotech (TSXV:IOT)
Historical Stock Chart
From Jun 2024 to Jul 2024

Innovotech (TSXV:IOT)
Historical Stock Chart
From Jul 2023 to Jul 2024